1370290-30-4

Basic information

• Product Name: 2-(4-(2-(3-(3-(2-methylbenzo[d]thiazol-6-ylamino)-3-oxopropyl)ureido)ethyl)benzyl)malonic acid
• CAS NO: 1370290-30-4
• Molecular Weight: 498.56
• Mol File: 1370290-30-4.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 2-(4-(2-(3-(3-(2-methylbenzo[d]thiazol-6-ylamino)-3-oxopropyl)ureido)ethyl)benzyl)malonic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-(2-(3-(3-(2-methylbenzo[d]thiazol-6-ylamino)-3-oxopropyl)ureido)ethyl)benzyl)malonic acid(1370290-30-4)
• EPA Substance Registry System: 2-(4-(2-(3-(3-(2-methylbenzo[d]thiazol-6-ylamino)-3-oxopropyl)ureido)ethyl)benzyl)malonic acid(1370290-30-4)

Safety Data

• Hazardous Substances Data: 1370290-30-4(Hazardous Substances Data)

Upstream product

• 132690-91-6 4-[2-(tert-butyloxycarbonylamino)ethyl]benzoic acid 
• 60531-36-4 4-(2-amino-ethyl)-benzoic acid hydrochloride 
• 1370290-49-5 N-(3-(2-methylbenzo[d]thiazol-6-ylamino)-3-oxopropyl)-1H-imidazole-1-carboxamide 
• 1370290-45-1 diethyl 2-(4-(2-(tert-butoxycarbonylamino)ethyl)benzyl)malonate 
• 1370290-43-9 diethyl 2-(4-(2-(tert-butoxycarbonylamino)ethyl)benzylidene)malonate 
• 421551-76-0 tert-butyl N-{2-[4-(hydroxymethyl)phenyl]ethyl}carbamate 
• 177736-04-8 methyl 4-[2-(tert-butoxycarbonylamino)ethyl]benzoate 
• 1156197-42-0 3-amino-N-(2-methylbenzo[d]thiazol-6-yl)propanamide 
• 1370290-40-6 tert-butyl 3-(2-methylbenzo[d]thiazol-6-ylamino)-3-oxopropylcarbamate 
• 1370290-46-2 C₁₆H₂₃NO₄*ClH 
• 1370290-57-5 diethyl 2-(4-(2-(3-(3-(2-methylbenzo[d]thiazol-6-ylamino)-3-oxopropyl)ureido)ethyl)benzyl)malonate 
• 2941-62-0 6-amino-2-methylbenzothiazole 
• 421551-75-9 tert-butyl (4-formylphenethyl)carbamate 

Relevant articles and documents

Design and synthesis of novel lactate dehydrogenase a inhibitors by fragment-based lead generation

Lactate dehydrogenase A (LDHA) catalyzes the conversion of pyruvate to lactate, utilizing NADH as a cofactor. It has been identified as a potential therapeutic target in the area of cancer metabolism. In this manuscript we report our progress using fragment-based lead generation (FBLG), assisted by X-ray crystallography to develop small molecule LDHA inhibitors. Fragment hits were identified through NMR and SPR screening and optimized into lead compounds with nanomolar binding affinities via fragment linking. Also reported is their modification into cellular active compounds suitable for target validation work.